Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. [electronic resource]
Producer: 20110201Description: 88 p. digitalISSN:- 1477-7819
- DNA, Neoplasm -- genetics
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Humans
- Mesothelioma -- drug therapy
- Mutation
- Peritoneal Neoplasms -- drug therapy
- Polymerase Chain Reaction
- Protein Kinase Inhibitors -- therapeutic use
- Quinazolines -- therapeutic use
- Retrospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.